Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824483 · ClinicalTrials.gov registry record · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
A Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL), sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 8
- Study locations
NCT03824483: Recruiting Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL), sponsored by Memorial Sloan Kettering Cancer Center.
NCT03824483 is a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL) that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 230 participants, above the 184-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (25% higher). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03824483, a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL), is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Primary Outcome
Patients will have their minimum residual disease (MRD) response classified by bone marrow peripheral blood flow cytometry with a sensitivity of 10-4.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
- DRUG Venetoclax
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
Illinois
- Northwestern University - Evanston
Massachusetts
- Massachusetts General Hospital (Data Collection and Specimen Analysis) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2019-02-22 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What NCT03824483 shows while recruiting
NCT03824483 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 184-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (25% higher).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT03824483 lists 8 locations in 4 states (New York, New Jersey, Illinois).
Frequently Asked Questions
What is clinical trial NCT03824483 about?
NCT03824483 is a clinical study titled "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)". The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
What is the current status of trial NCT03824483?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2019-02-22. Estimated completion is 2027-02.
What conditions does trial NCT03824483 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL).
What interventions are being tested in trial NCT03824483?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Venetoclax (DRUG).
Who is sponsoring clinical trial NCT03824483?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03824483 being conducted?
This trial has 8 study locations across Illinois, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03824483's enrollment target sits among peer trials
230 6th of 29 higher than 24 of 29 other Chronic Lymphocytic Leukemia (CLL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
RECRUITING · Phase 2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
ACTIVE NOT RECRUITING · Phase 2
-
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
ACTIVE NOT RECRUITING · Phase 2
-
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
- NCT03871075 · 230 participants · NA
Intermittent Pneumatic Compression With and Without Exercise to Improve Functioning in Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI